Opens in a new tab or window Roughly half as many patients with cirrhosis in remission from overt hepatic encephalopathy (OHE) experienced a breakthrough episode with rifaximin monotherapy ...

MONDAY, Oct. 28, 2024 (HealthDay News) -- For patients with a history of overt hepatic encephalopathy (OHE), rifaximin ...

Get detailed information on Rifaximin, including pronunciation ... certain bacteria and liver disease affecting the brain (hepatic encephalopathy). It prevents the growth of bacteria inside ...

This post hoc analysis of data from two randomized trials evaluated the efficacy of Xifaxan monotherapy compared to lactulose monotherapy for risk reduction of overt hepatic encephalopathy (OHE ...

Rifaximin is a minimally absorbed antibiotic that is FDA-approved for treatment of travelers' diarrhea and prevention of hepatic encephalopathy. The primary endpoint (patient-reported "adequate ...

This post hoc analysis of data from two randomized trials evaluated the efficacy of Xifaxan monotherapy compared to lactulose monotherapy for risk reduction of overt hepatic encephalopathy (OHE) ...

Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizations Skip to main content You have permission to edit this article. Edit Close Facebook Twitter YouTube Instagram ...